Literature DB >> 25822422

[Infective endocarditis].

D Horstkotte1, C Piper.   

Abstract

Colonization of native cardiac valves or polymer implants, e.g. valves, conduits, rings, electrode leads and polymer-associated endocarditis (PIE), by microorganisms, primarily gram-positive bacteria (infective endocarditis), constitutes a severe, prognostically unfavorable disease. Fever and in the majority of cases development of a valve regurgitant murmur are clinical landmark findings. The white blood cell count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are regularly elevated. With a normal CRP level, infective endocarditis is extremely unlikely. Irrespective of body temperature, at least three blood cultures (aerobic and anaerobic) should be taken and if initiation of antimicrobial therapy is urgent, 1 h apart before therapy is initiated. Identification of the pathogen to the species level and testing antimicrobial susceptibility to antibiotics by a quantitative hemodilution test, not with agar diffusion tests, are obligatory. A minimum inhibitory concentration should be administered for antibiotics and usual combinations of antibiotics with an expected synergistic potential. Streptococci, staphylococci and enterococci are the most frequent causative organisms. Immediate initiation of transthoracic echocardiography (TTE) is mandatory followed by transesophageal echocardiography if imaging quality is poor, involvement of intracardiac implants is possible or TTE is insufficient to establish the diagnosis. An insufficiently long antimicrobial therapy promotes recurrent infections, thus a 4-week treatment is standard, while in special cases (e.g. PIE) treatment for 6 weeks should be the rule. If typical complications of infective endocarditis, such as uncontrolled local infection, systemic thromboembolism, central nervous involvement, development of a severe valve incompetence or mitral kissing vegetation in primary aortic valve endocarditis occur, urgent surgical intervention should be considered. If cardiac implants are involved, early surgical removal followed by a 6-week antimicrobial treatment is the rule. Adequate and timely diagnosis and treatment are the key to improve the overall prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25822422     DOI: 10.1007/s00059-015-4217-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  28 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study.

Authors:  Evelyn E Hill; Paul Herijgers; Piet Claus; Steven Vanderschueren; Willy E Peetermans; Marie-Christine Herregods
Journal:  Am Heart J       Date:  2007-11       Impact factor: 4.749

3.  Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis.

Authors:  Mariana Mirabel; Romain Sonneville; David Hajage; Emmanuel Novy; Florence Tubach; Philippe Vignon; Pierre Perez; Sylvain Lavoué; Achille Kouatchet; Olivier Pajot; Armand Mekontso-Dessap; Jean-Marie Tonnelier; Pierre-Edouard Bollaert; Jean-Pierre Frat; Jean-Christophe Navellou; Herve Hyvernat; Ali Ait Hssain; Jean-François Timsit; Bruno Megarbane; Michel Wolff; Jean-Louis Trouillet
Journal:  Eur Heart J       Date:  2013-08-20       Impact factor: 29.983

4.  The importance of secondary mitral valve involvement in primary aortic valve endocarditis; the mitral kissing vegetation.

Authors:  C Piper; R Hetzer; R Körfer; R Bergemann; D Horstkotte
Journal:  Eur Heart J       Date:  2002-01       Impact factor: 29.983

5.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

6.  Diagnosing endocarditis with the cloned 112 kDa antigen of Enterococcus faecalis.

Authors:  J P Burnie; I Clark
Journal:  J Immunol Methods       Date:  1989-10-24       Impact factor: 2.303

Review 7.  New insight into the diagnosis of fastidious bacterial endocarditis.

Authors:  Philippe Brouqui; Didier Raoult
Journal:  FEMS Immunol Med Microbiol       Date:  2006-06

8.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

9.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.

Authors:  D T Durack; A S Lukes; D K Bright
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

10.  Increased risk of bacterial endocarditis in inflammatory bowel disease.

Authors:  G Kreuzpaintner; D Horstkotte; A Heyll; B Lösse; G Strohmeyer
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.